# Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

> **NCT00170157** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 112 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage III Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** Flutamide
- **DRUG:** Goserelin Acetate
- **DRUG:** Ipilimumab
- **DRUG:** Leuprolide Acetate
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00170157
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2011-04
- **Final completion:** 2013-06
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170157, "Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00170157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*